Regeneron Pharma stock has been in a persistent downtrend for over 280 days. Here's why you should avoid REGN.

Analysts have set 12-month price targets for Regeneron Pharmaceuticals, revealing an average target of $808.67, a high ...

New licensing agreement with Hansoh Pharma provides Regeneron with HS-20094, a GLP-1/GIP receptor agonist in advanced st ...

Viz.ai is to enter a multi-year collaboration with Sanofi and Regeneron aimed at deploying and assessing an AI-powered ...

Federal jurors in Delaware found that Amgen violated antitrust laws by bundling its cholesterol treatment with substantial ...

Tarrytown-based Regeneron Pharmaceuticals, Inc. has announced it has been named the successful bidder in the bankruptcy ...

Regeneron, a biotech company, will acquire 23andMe for $256 million and vowed to comply with the genetic testing company's privacy policies.

“Regeneron is committed to advancing better ... sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a ...

Regeneron will not acquire 23andMe's Lemonaid Health telehealth business. "We have deep experience with large-scale data management," Regeneron co-founder George Yancopoulos said in a statement.